Botulinum toxin blocks mast cells and prevents rosacea like inflammation

被引:77
作者
Choi, Jae Eun [1 ]
Werbel, Tyler [2 ]
Wang, Zhenping [1 ]
Wu, Chia Chi [1 ]
Yaksh, Tony L. [3 ]
Di Nardo, Anna [1 ]
机构
[1] Univ Calif San Diego, Dept Dermatol, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[3] Univ Calif San Diego, Dept Anesthesiol & Pharmacol, San Diego, CA 92103 USA
关键词
Botox; Botulinum toxin; Mast cell; Mechanism of action; Rosacea; SKIN INFLAMMATION; CATHELICIDIN; RECEPTOR; MECHANISMS; RELEASE; DEGRANULATION; INHIBITION; ERYTHEMA; LL-37;
D O I
10.1016/j.jdermsci.2018.12.004
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown. Objectives: To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions. Methods: Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by beta-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections. Results: Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers. Conclusions: These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. (C) 2019 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:58 / 64
页数:7
相关论文
共 51 条
  • [1] Allergan Inc, 2017, BOT
  • [2] [Anonymous], 2017, BOT COSM
  • [3] Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
    Aoki, KR
    [J]. NEUROTOXICOLOGY, 2005, 26 (05) : 785 - 793
  • [4] ALCOHOL-INDUCED ROSACEA FLUSHING BLOCKED BY NALOXONE
    BERNSTEIN, JE
    SOLTANI, K
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1982, 107 (01) : 59 - 61
  • [5] Skin neurogenic inflammation
    Choi, Jae Eun
    Di Nardo, Anna
    [J]. SEMINARS IN IMMUNOPATHOLOGY, 2018, 40 (03) : 249 - 259
  • [6] Dayan SH, 2017, J DRUGS DERMATOL, V16, P549
  • [7] Dayan SH, 2012, J DRUGS DERMATOL, V11, pS10
  • [8] Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial
    Di Nardo, Anna
    Holmes, Anna D.
    Muto, Yumiko
    Huang, Eugene Y.
    Preston, Norman
    Winkelman, Warren J.
    Gallo, Richard L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (06) : 1086 - 1092
  • [9] SV2 is the protein receptor for botulinum neurotoxin A
    Dong, M
    Yeh, F
    Tepp, WH
    Dean, C
    Johnson, EA
    Janz, R
    Chapman, ER
    [J]. SCIENCE, 2006, 312 (5773) : 592 - 596
  • [10] INDUCTION OF MAST-CELL DEGRANULATION IN SKIN BY ULTRASOUND
    DYSON, M
    LUKE, DA
    [J]. IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL, 1986, 33 (02) : 194 - 201